Aardvark Expands Phase 3 Trial for Prader-Willi Syndrome Treatment to Younger Patients
Event summary
- Aardvark Therapeutics received FDA submission and IRB approval to amend its Phase 3 HERO trial protocol, lowering the minimum age of eligibility from 10 to 7 years old for patients with Prader-Willi Syndrome (PWS).
- The HERO trial, a randomized, double-blind, placebo-controlled study, aims to enroll 90 patients across the U.S., Australia, Canada, the United Kingdom, and South Korea.
- ARD-101, the lead candidate, is a gut-restricted small molecule agonist targeting taste receptors to reduce hyperphagia in PWS patients.
- Topline data from the HERO trial is expected in the third quarter of 2026.
The big picture
Aardvark's protocol amendment reflects a strategic shift to capture earlier intervention in PWS, a rare genetic disorder with limited therapeutic options. The move aligns with broader industry trends toward pediatric-focused rare disease treatments, potentially broadening the addressable market for ARD-101. The company's focus on gut-brain signaling pathways positions it uniquely in the metabolic disease space, though execution risks remain high given the trial's complexity and regulatory hurdles.
What we're watching
- Trial Execution
- Whether the expanded eligibility criteria will accelerate enrollment and topline data readout in the HERO trial.
- Regulatory Pathway
- How the FDA's response to the amended protocol may influence future regulatory strategies for ARD-101.
- Competitive Positioning
- The pace at which Aardvark can differentiate ARD-101 in the PWS treatment landscape.
Related topics